Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Peck Ong

Pediatric Allergy/Immunology Los Angeles, CA Medical Doctor

NPI 1659478865 CMS profile 1008263

4650 Sunset Blvd, Los Angeles, CA 90027

Open in the dashboard

General payments

$83,123

77 records reported · program years 2019–2024

Research payments

$8,651

Paid to them · 21 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$484,979 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Peck Ong of Los Angeles, CA is reported in the CMS Open Payments database as having received $83,123 across 77 general payments and $8,651 in research payments paid to them. Separately, studies naming them as principal investigator received $484,979 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Pediatric Allergy/Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $28,673 38
2023 General $2,875 1
2022 General $1,159 5
2022 Research $2,210 3
2021 General $9,500 4
2021 Research $4,880 8
2020 General $23,606 13
2019 General $17,310 16
2019 Research $1,561 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peck Ong
  • Pediatric Allergy/Immunology median
  • Middle half of Pediatric Allergy/Immunology
  • National median

In program year 2025, general payments to Peck Ong were reported at $0. Among 289 Pediatric Allergy/Immunology profiles paid that year, the median was $361 and the middle half received between $125 and $2,493.

Show as a table
Year Peck Ong Pediatric Allergy/Immunology median Middle half National median
2019 $17,310 $325 $92–$1,399 $163
2020 $23,606 $144 $66–$2,490 $114
2021 $9,500 $357 $95–$2,633 $132
2022 $1,159 $385 $125–$2,259 $149
2023 $2,875 $470 $121–$2,946 $160
2024 $28,673 $317 $125–$2,583 $164
2025 $0 $361 $125–$2,493 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Pfizer Inc. $23,213 8 payments
  2. Dermavant Sciences, Inc. $18,992 23 payments
  3. AbbVie, Inc. $13,413 16 payments
  4. Regeneron Pharmaceuticals, Inc. $10,336 12 payments
  5. Amgen Inc. $9,680 15 payments
  6. Incyte Corporation $3,229 1 payment
  7. Genzyme Corporation $2,499 1 payment
  8. Janssen Global Services, LLC $1,760 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $63,335 17 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,140 1 payment
  3. Travel and Lodging $6,878 27 payments
  4. Honoraria $2,590 1 payment
  5. Food and Beverage $2,180 31 payments
Products named General payments · program years 2019–2024
  1. EUCRISA $20,623 7 payments
  2. TAPINAROF $18,992 23 payments
  3. DUPIXENT Inflammation And Immunology $10,336 12 payments
  4. RINVOQ $4,888 2 payments
  5. DUPIXENT Immunology $2,499 1 payment
  6. SKYRIZI $1,159 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Regeneron Pharmaceuticals, Inc. $7,090 11 payments
  2. LEO Pharma AS $1,561 10 payments

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Allergy/Immunology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record